SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Adam Glanzman/Getty Images
Job Trends
Moderna Rapidly Expands COVID-19 Vaccine Plant Production, Adds 155 Jobs
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
June 21, 2021
 · 
2 min read
 · 
Kate Goodwin
Biogen is planning to cut its Alzheimer's drug Adu
FDA
Rival Drugs of Biogen’s Aduhelm May Help Prove FDA’s Highly Criticized Approval
Three other drug contenders that work similarly to Biogen’s drug are currently in clinical trials and expecting data relatively soon.
June 18, 2021
 · 
3 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Deals
Push to Public Continues as Biotech Dominates the IPO List This Week
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
June 17, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: June 9-15
Each week more money pours into the biopharma world. Here’s a peek at who’s getting a taste of fresh funds this week.
June 16, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Cash is King for Up-and-Coming Biotechs: Four Financing Rounds Announced Today
Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.
June 15, 2021
 · 
4 min read
 · 
Kate Goodwin
Niels Wenstedt/BSR Agency/Getty Images
Policy
EU Hits AstraZeneca Vaccine with Another Blood Condition for Side Effect List
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
June 14, 2021
 · 
2 min read
 · 
Kate Goodwin
According to NIH Bumetanide can help fight against
Genetown
Could Elemental Metals Be Key to Effective Alzheimer’s Treatments?
This is the first confirmation of elemental metals in human brain tissue. Researchers hope it can contribute to the ongoing Herculean task of finding a cure for Parkinson’s and Alzheimer’s.
June 11, 2021
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Ocugen Faces Major Slowdown for COVID-19 Vaccine as FDA Recommends BLA
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
June 10, 2021
 · 
2 min read
 · 
Kate Goodwin
Money on the Move: June 2-8
Things are warming up quickly this summer for life sciences investors. Here’s who’s coming in hot with cash this week.
June 9, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Data Companies Merge to Create Nation’s Largest Health Care Data Ecosystem
The $7 billion transaction by Datavant with Ciox Health will be the nation’s largest “neutral and secure health data ecosystem.”
June 9, 2021
 · 
3 min read
 · 
Kate Goodwin
Policy
Study: COVID-19 More Dangerous for Those With High Cholesterol, Heart Disease
A real-world study published by the FH Foundation confirms COVID-19 increased heart attack rates significantly in patients with these conditions.
May 28, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
BlueRock and Senti Collaborate to Build Smarter, Disease-Fighting Cell Therapies
Determined to take its next-generation engineered cell therapies to the next level, BlueRock teams up with Senti Biosciences with futuristic medicines in mind.
May 27, 2021
 · 
2 min read
 · 
Kate Goodwin
Igor Golovniov/SOPA Images/LightRocket via Getty I
Business
Money on the Move: May 19-25
Drug development requires solid funding. Here’s who’s standing on higher ground this week with fresh investment dollars.
May 26, 2021
 · 
5 min read
 · 
Kate Goodwin
Business
Engine and Giiant Scoop Up Fresh Funding for Cancer and IBD
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
May 26, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
“Paradigm Shift” Needed in Air Purity to Reduce Spread of COVID-19, Study Says
Researchers are calling for a “paradigm shift” in indoor ventilation systems to combat COVID-19 and other airborne pathogens.
May 17, 2021
 · 
4 min read
 · 
Kate Goodwin
Load More